• BMD trajectory can replace fracture as outcome in osteoporosis clinical trials

    1 month ago - By Healio

    Bone mineral density at the femoral neck and total hip is a potential surrogate for fracture risk in clinical trials of osteoporosis drugs, according to findings presented at the American Society for Bone and Mineral Research Annual Meeting.
    Using pooled data from 21 randomized, placebo-controlled osteoporosis drug trials, Dennis Black, PhD, professor and division head of clinical trials and multicenter studies in the department of epidemiology and biostatistics at the University of California, San Francisco, and colleagues estimated percent of treatment explained by change in BMD over 2
    Read more ...